Effect of transforming growth factor-β1, fibronectin and plasminogen activator inhibitor on migration of bovine aortic endothelial cells by Brozowski, Christine E.
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1996
Effect of transforming growth factor-β1, fibronectin
and plasminogen activator inhibitor on migration
of bovine aortic endothelial cells
Christine E. Brozowski
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Brozowski, Christine E., "Effect of transforming growth factor-β1, fibronectin and plasminogen activator inhibitor on migration of
bovine aortic endothelial cells" (1996). Yale Medicine Thesis Digital Library. 2428.
http://elischolar.library.yale.edu/ymtdl/2428
YALE MEDICAL LIBRARY 
08676 1013 
GROWTH FACT 
ACTIVA 
■EFFECT-OS 
: fibrone PLASM iNOGli 
OVINE.AORTIC' ENDOTHEUAi 
CHRISTINE 
YALE 
UNIVERSITY 
CUSHING/WHITNEY 
MEDICAL LIBRARY 
Digitized by the Internet Archive 
in 2017 with funding from 
The National Endowment for the Humanities and the Arcadia Fund 
https://archive.org/details/effectoftransforOObroz 





Effect of Transforming Growth Factor-pl, Fibronectin 
and Plasminogen Activator Inhibitor on Migration of 
Bovine Aortic Endothelial Cells. 
A Thesis Submitted to the 
Yale University School of Medicine 
in Partial Fulfillment of the Requirements for the 
Degree of Doctor in Medicine 
by 
Christine E. Brozowski 
May 1996 
VALE MEDICAL LIBRARY 
AUG 1 3 1996 
HEP 
"T113 
+ YIZ 
bis 7 
Abstract 
EFFECT OF TRANSFORMING GROWTH FACTOR-(3l, FIBRONECTIN AND 
PLASMINOGEN ACTIVATOR INHIBITOR ON MIGRATION OF BOVINE AORTIC 
ENDOTHELIAL CELLS. Christine Brozowski (Sponsored by Joseph 
A. Madri). Department of Pathology, Yale University, School 
of Medicine, New Haven, CT. 
Restenosis remains the largest complication of endarterectomy 
and balloon catheter angioplasty. Vascular trauma caused by 
procedures such as these result in deundation injury which may 
lead to hyperplasia and the development of a neointima. 
Neointimal formation depends on smooth muscle cell 
proliferation, migration, and matrix synthesis, and the 
presence of endothelium. Growth factors have been shown to 
have an influence on smooth muscle cells and endothelial 
cells. The target of this investigation was the effect of 
transforming growth factor (TGF-(3l), fibronectin (Fn) , and 
plasminogen activator inhibitor (PAI-2) on migration of bovine 
aortic endothelial cells. TGF- (31 decreased migration by 28% + 
3%. Fibronectin decreased migration by 19% +. 4%. Both values 
were significant (p<0.05) using a student's t-test. PAI-2 at 
lOug/ml did not significantly decrease migration (6% ± 4%). 
Later studies in our laboratory using higher levels of PAI-2 
of 50ug/ml resulted in a decreased migration of 10% + 3%, 
which was statistically significant. TGF-(3l has been shown to 

be present in significant quantities at sites of vascular 
injury in vivo. TGF- (31 decreases the rate of endothelial cell 
migration and increases the rate of smooth muscle cell 
migration. Therefore, the presence of TGF-(3l at the site of a 
vascular lesion increases the likelihood of restenosis. Since 
fibronectin can partially mimic the effects of TGF-pl on BAEC 
migration, this suggests that the TGF- Pi effect on migration 
is mediated by modulation of the extracellular matrix. The 
effect of TGF- Pi on endothelial cell migration may also be due 
to increased expression of PAI or decreased uPA expression, as 
PAI-2 decreases BAEC migration. 
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Introduction 
Balloon angioplasty, endarterectomy, and synthetic grafting are therapeutic interventions 
currently performed to alleviate the effects of atherosclerosis. It has been estimated that over 
350,000 coronary angioplasty procedures were performed in the United States in 1995.1 
Restenosis remains the most important limitation of angioplasty, with studies suggesting that 
up to 50% of patients will develop restenoses within one year, with up to 20% of patients 
necessitating a repeat operation within 6 months.2,3 Procedures such as angioplasty result in 
endothelial denudation injury to the blood vessel walL Stenosing intimal lesions may develop 
from intimal hyperplasia which narrows the vessel lumen, and can compromise blood flow. 
This ultimately results in a failure of the reconstruction.4 The formation of a neointima after 
vascular injury depends on smooth muscle cell proliferation and migration and the synthesis of 
a new extracellular matrix.4 
The normal tunica intima is composed of endothelial cells and smooth muscle cells.5 
Endothelial cells line the vascular system, forming a nonthrombogenic surface for blood flow 
and covering smooth muscle cells. Smooth muscle cells compose the media of large vessels, 
maintain vessel wall integrity, control vascular tone and influence endothelial cell behavior. 
Following denudation injury, medial smooth muscle cells proliferate and migrate rapidly into 
the intima where they synthesize components which may narrow the vessel lumen. Endothelial 
cells migrate more slowly from the edges of the wound to reconstitute the damaged endothelial 
cell layer and reestablish vessel wall integrity, critical to maintaining lumen patency.6 Stimuli 
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which retard migration of endothelial cells and enhance the migration of smooth muscle cells 
lead to the development of stenotic lesions at the site of vascular injury.7 
Transforming growth factor (TGF-(3l), a component of platelet a granules, is synthesized and 
secreted by endothelial and smooth muscle cells.7 TGF-[3l regulates critical cell functions 
including growth, differentiation, activation, and migration.8 Specifically, TGF-(3l has been 
shown to be present in significant quantities at sites of vascular injury in vivo, and markedly 
inhibits endothelial cell migration and vessel wall repair following injury.9 It has been suggested 
that the TGF-(3l mediated decrease in endothelial cell migration is associated with increased 
expression of fibronectin (Fn) and plasminogen activator inhibitor (PAI-2)8. This report 
documents the effect of transforming growth factor (TGF-(31), fibronectin (Fn), and 
plasminogen activator inhibitor (PAI-2) on migration of bovine aortic endothelial cells as an in 
vitro model of re-endothelialization and repair of denudation injury such as that produced by 
balloon catheter angioplasty. 
Methods 
Bovine aortic endothelial cells (BAEC) were isolated and cultured with DMEM and 10% fetal 
calf serum (FCS). The cells were seeded into the middle of a steel fence with a known area 
and allowed to attach to the underlying type I collagen matrix below, and grow to confluency 
for 4-5 hours. The fence was then removed. With the loss of contact inhibition, cell migration 
radially outward was initiated. The cells were covered in media alone or with media plus 
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exogenous transforming growth factor (TGF-[3l) at a final concentration of 0.5 ng/mL, 
plasminogen activator inhibitor (PAI-2) at a final concentration of 10 ug/ml, fibronectin (Fn) at 
a final concentration of 50 ug/ml, Aprotinin at 50 ug/ml, or EACA at 50 ug/ml. The cells 
migrated radially outward for six days, and were fed with additional media plus the appropriate 
growth factors at day three. Migrations were stopped 6 days post initiation of treatment. The 
cultures were then washed in PBS and fixed with 10% Buffered Formalin. Cells were stained 
with Harris' hematoxylin to evaluate cell migration. 
Petri dishes with stained cells were placed on an overhead projector to assess surface area 
covered by the cells. The surface areas were transferred to paper and a computer graphics 
tablet was used to quantify surface areas obtained by overhead projection. These surface areas 
were compared with known values of the initial fence area to obtain the net increase in surface 
area. Maximal response was obtained using DMEM media and 10% FCS only, thus, this was 
defined as the control with 100% relative migration. Migration in the presence of growth 
factors (TGF-(3l, Fn, PAI-2, EACA and Aprotinin) was compared and normalized to this 
value. Bar graphs were generated from mean values. The differences in means were analyzed 
using a student's t-test. Statistical significance was assumed for P<0.05. 
Results 
Treatment with TGF-pl decreased the distance of migration of BAEC on a type 1 collagen 
matrix by 28% + 3% compared to control. Fibronectin showed a 19% + 4% inhibition of 
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migration distance. These were significant (p<0.05) using a student's t-test. In contrast, 
treatments with EACA, Aprotinin and EACA & Aprotinin did not show a significant decrease 
in migration compared to the control group. EACA and Aprotinin are non-specific protease 
inhibitors. These results suggest that non-specific protease inhibitors do not decrease the 
migration of endothelial cells. See Figure 1. 
PAI-2 at lOug/ml showed only a 6% ± 4% decrease in migration which was not statistically 
significant. In later BAEC migration studies in our laboratory, however, PAI-2 concentration 
was increased to 50ug/ml with a significant decrease in migration of 10% + 3%. In additional 
studies, Petzelbauer et al demonstrated that stable over-expression of PAI-1 protein in BAEC 
using retroviral transduction resulted in a significant inhibition of BAEC migration. The 
g 
resultant BAEC migration was found to decrease 23% ± 2%. 
Discussion 
Repair of arterial injury produced by balloon angioplasty or atherectomy leads to the 
development of an intimal thickening and a subsequent narrowing of the vessel lumen.10 
Neointimal formation depends on smooth muscle cell proliferation, migration, and matrix 
synthesis, and the presence/absence of an endothelium4 The two major cell types of the vessel 
wall, the smooth muscle cell and the endothelial cell, respond differently to injury. Medial 
SMCs begin to migrate from the media into the intima. Many cells proliferate, but up to one 
half do not divide 4 Once in the intima, SMCs continue to proliferate and form a thick layer. 
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The resulting neointima is further enlarged by extracellular matrix components synthesized by 
the smooth muscle cells. Endothelial cells, on the other hand, migrate more slowly from 
around the area of denudation to reconstitute the damaged endothelial cell layer. The cells at 
the edge of the wound divide and migrate inward, but the central portion of large injuries may 
remain uncovered.4'11 Importantly, proliferation of intimal smooth muscle cells ceases earlier in 
areas covered by regenerating endothelium than in regions lacking an endothelium.4 
Primary lesions differ from restenotic lesions in that primary lesions consist of well-organized 
collagen and ground substance, and are hypocellular, while restenotic lesions have foci of 
hypercellularity consisting of proliferative vascular smooth muscle cells with associated matrix 
proteins.12 These smooth muscle cells have an unusual elongated shape with processes 
extending from the cells and are accompanied by significant matrix deposition composing 50- 
60% of lesion size between the cells.12 Advanced atherosclerotic lesions show progressive 
development of small denuded regions. This loss of continuity of the endothelium in the 
evolution of atherosclerosis suggests that some property of the atheromatous wall or blood 
interacting with the wall is responsible for the inhibition of endothelial regeneration.1' 
Both platelet deposition and growth factor release have been suggested as important events 
initiating the cellular growth response after injury.12,14 A variety of growth factors have been 
described in vascular smooth muscle cells and/or atherosclerotic tissue, and have, therefore, 
been inferred to play a role in the development of restenosis lesions. These include the 
transforming growth factor-(3s, platelet-derived growth factors and receptors, fibroblast growth 
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factors, and insulin-like growth factors.15 Platelet-derived growth factor (PDGF) has been 
found to exert little effect on smooth muscle cell replication, but markedly influences the ability 
of SMCs to migrate into the intima.16 TGF-(3l is a major component of platelet releasates and 
is synthesized and secreted by endothelial cells and smooth muscle cells.7 TGF-(3l has been 
shown to inhibit proliferation of endothelial cells, and to retard epithelial wound healing in 
vitro.17 TGF-(3l influences matrix production and protease inhibitors, both of which affect 
migration of endothelial cells. Additionally, TGF-(3l has been demonstrated to stimulate the 
proliferation of smooth muscle cells and the production of elastin and proteoglycan, common 
features of atherosclerotic plaques.15 
TGF-(3l has been shown to be present in significant quantities at sites of vascular injury in 
vivo.8,10,18 In addition to decreasing endothelial cell migration, TGF-(3l has been documented to 
increase vascular smooth muscle cell migration.19 Stimuli which enhance migration of medial 
smooth muscle cells into the intima where they can synthesize matrix components leading to 
the development of a stenotic lesion at the site of vascular injury may result in the eventual 
occlusion of the vessel lumen.6 Because TGF-(3l decreases the rate of endothelial cell 
migration and increases the rate of smooth muscle cell migration, the presence of TGF-(3l at 
the site of a vascular lesion increases the likelihood of restenosis. Additional steps involved in 
restenosis include the release of growth factors, proteoglycan deposition and release of growth 
factors, proteoglycan deposition and extracellular matrix remodeling.2,20 Potential inhibitors at 
each step could be used as preventative therapy. 

TGF-(3l influences matrix production and protease inhibitors, both of which affect migration of 
endothelial cells. TGF-(3l has been observed to down-regulate the expression of uPA activity 
in endothelial cellS.21 Endothelial cells express tissue-type plasminogen activator (tPA), 
urokinase-like plasminogen activator (uPA) and plasminogen activator inhibitor (PA1). uPA 
interaction with the uPA receptor has been associated with an increase in endothelial cell 
motility.8 PAI-2 is a protease inhibitor which is specific for uPA receptor sites, and decreases 
BAEC migration. TGF-(3l decreases the expression of uPA and subsequently lessens the rate 
of migration of endothelial cells. Thus, the TGF-(5l effect on BAEC migration may be due to 
the combined effects of increased expression of PA1, decreased uPA expression, and 
influencing the extracellular matrix (increased fibronectin deposition). In other studies in our 
laboratory, Petzelbauer et al showed that unlike endothelial cells, bovine aortic smooth muscle 
cells exhibited an increased rate of migration in response to the addition of exogenous TGF-(3l, 
fibronectin or PAI-2, or by the stable over-expression of PAI-1 protein. 
Endothelial cell replication and migration are triggered by damage to the vessel walL These 
cells migrate from the leading edge of a lesion to reestablish the endothelial monolayer, and 
repair the vessel wall It has been shown that TGF-(3 inhibits both endothelial replication and 
migration, thus decreasing endothelial regeneration.13 Heimark,13 et al demonstrated that 
TGF-(3 transiently decreases DNA synthesis in endothelial cells. Specifically, TGF-(3 delays the 
entry of regenerating endothelial cells into the S phase. Once cells have passed into S or G2, 
however, they are no longer responsive to TGF-(3. 
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Increased TGF-|3l gene expression has been found in rat carotid arteries after balloon catheter 
injury.8,10 In studies by Nikol,15 et aL, human atherosclerotic tissue specimens were examined 
for TGF-(3l mRNA. Primary atherosclerotic lesions showed slightly, but not significantly, 
higher TGF-(3l expression than non-atherosclerotic tissue. TGF-(3l was maximally expressed 
in restenotic tissues. TGF-(3l expression in restenotic atherosclerotic tissues was significantly 
greater than that found in primary atherosclerotic tissue, consistent with the hypothesis that 
increased TGF-(3l mRNA expression is related to smooth muscle cell proliferation.15 These 
results suggest a role for TGF-(3l in the development of restenosis lesions. 
Neointimal formation requires the synthesis of a new extracellular matrix. Major constituents 
of matrices produced by intimal SMCs include fibronectin, elastin and type I collagen.10 The 
addition of exogenous TGF-(3l to arterial SMC in vitro has been shown to stimulate 
extracellular protein synthesis.10 TGF-(3l has been shown to increase fibronectin production in 
endothelial cells, smooth muscle cells and fibroblasts.8,22 Fibronectin promotes rapid 
attachment of bovine aortic endothelial cells, but little migration.21 BAECs treated with TGF- 
(31 have shown increased fibronectin mRNA levels, and synthesis and deposition of 
fibronectin8,19. Increased mRNA levels of fibronectin and collagen a2(I) have been found to 
correlate with the onset of neointimal formation.10 
In this paper we have shown that the addition of exogenous TGF-(3l or fibronectin decreases 
BAEC migration. Fibronectin can partially mimic the effects of TGF-(3l on BAEC migration 
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suggesting that the TGF-(3l effect on migration is mediated by modulation of the synthetic 
matrix. TGF-(3l alters matrix production by increasing fibronectin deposition, increasing PAI 
expression, and decreasing uPA expression.8 The majority of medical therapies designed to 
prevent restenosis are aimed at reducing smooth muscle cell migration as the primary cause of 
restenoses pathology. However, enhancement of endothelial cell regeneration and decreased 
matrix production are other potential targets to consider as proliferation of smooth muscle cells 
ceases earlier in areas covered by an regenerating endothelium, and as the matrix composes a 
large part of the lesion volume. 
Conclusion 
This paper has demonstrated that TGF-(3l and fibronectin inhibit migration of bovine aortic 
endothelial cells. Other studies in our laboratory have shown that the addition of exogenous 
PAI-2 in high concentration (50ug/ml) also decreased BAEC migration, and that PAI & TGF- 
(31, and Fn & TGF-(3l were not additive. Therefore, we surmise that TGF-(3l alters matrix 
production by increasing fibronectin deposition, increasing PAI-2 expression and decreasing 
uPA expression. Conversely, TGF-(3l has been shown to enhance migration in smooth muscle 
cells. Previous studies have shown that the most intimal smooth muscle cell proliferation 
occurs in the region last covered by regenerating endothelium.24,25 Therefore, stimuli which 
retard the migration of endothelial cells and enhance the migration of smooth muscle cells lead 
to the development of stenotic lesions at the site of vascular injury. Consequently, reducing the 
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TGF-pl burden at the site of vascular lesion may decrease the incidence of restenosis following 
vascular injury. 
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